麻豆国产精品一二三在线观-麻豆国产精品一二三在线观看-麻豆国产精品一区二区-麻豆国产精品永久免费视频-麻豆国产巨作av剧情-麻豆国产蜜桃臀视频在线观看

德國MorphoSys AG
MorphoSys AG是一家上市生物技術企業， 位于慕尼黑Martinsried 區， 其業務是專門開發人體完全抗體， 發現治療危害生命疾病的新切入點， 開發治療這些疾病的以抗體為基礎的創新性藥品。 MorphoSys的目標是， 把自己的HuCAL抗體數據庫發展成研究和診斷以及藥品開發用新一代抗體的世界標準。 該企業和大多數知名制藥公司進行合作和共同研究， 其中有Boehringer Ingelheim、 Centocor/Johnson & Johnson、 Novartis、 Pfizer和Roche等。 在這些伙伴關系的框架中， MorphoSys跟蹤了50多個活性治療抗體項目。 該企業通過獨有的許可證和階段性結果付款以及根據所有產品銷售額所付的產品稅享受這些開發成績。 除此之外， MorphoSys通過業務單元AbD Serotec在研究 用抗體市場上開展業務。 AbD Serotec在德國(慕尼黑)、 美國(北 卡羅來 納州Raleigh)和英國(牛津)設有子公司。

MorphoSys AG, located in Martinsried/Munich, is one of the world's leading biotechnology companies focusing on fully human antibodies. With its unique technologies, MorphoSys is developing the next generation of antibodies, which can be used to treat diseases and for research and diagnostics purposes. Numerous partnerships have already been entered into with well-known companies from the pharmaceutical and biotechnology sectors, such as Boehringer Ingelheim, Daiichi Sankyo, Merck & Co, Novartis, Pfizer, and Roche.

The Company, founded in 1992, possesses the unique HuCAL technology (the Human Combinatorial Antibody Library). This library comprises several billion different, fully human antibodies. HuCAL is a very powerful technology, which allows rapid and automated production of high-affinity antibodies. The most important feature of the library is its capability of optimizing fully human antibodies to meet predefined specifications.

Presently, MorphoSys prosecutes its business in two operating segments. One segment, the Therapeutic Antibodies unit, develops drug candidates for commercial partners as well as MorphoSys's own proprietary product pipeline. In this regard, the Company has been successful in establishing a number of partnerships with renowned biotechnology and pharmaceutical companies and also generated several proprietary therapeutic antibody candidates for out-licensing to partners. MorphoSys's second operating segment, the Research Antibodies unit, delivers high-quality antibodies to the research market, under the brand AbD Serotec. Two successful acquisitions of U.S. and U.K.-based antibody suppliers have significantly strengthened and broadened MorphoSys’s position in the research antibody market. The resulting combined activities of MorphoSys’s AbD unit serve all segments of the research and diagnostics markets.
?